TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2808308

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 1096537

Group type: EXPERIMENTAL
Intervention: Lithium sulphate (24 mmol) after a standardized meal
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lithium sulphate (24 mmol) on an empty stomach
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lithium citrate in slow release tablets
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30783682

Group type: EXPERIMENTAL
Intervention: Vatelizumab (monoclonal antibody targeting α2 subunit of VLA-2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29260225

Group type: EXPERIMENTAL
Intervention: TTFields plus maintenance temozolomide (n=466)
Number of subjects: 695

Group type: COMPARATOR
Intervention: Temozolomide alone (n=229)
Number of subjects: 695
Study: 26006137

Group type: EXPERIMENTAL
Intervention: Postoperative statin therapy (atorvastatin 40 mg per day starting 6 hours after operation)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-statin group (no postoperative statin therapy)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Postoperative atorvastatin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Age as a predictor
Number of subjects: 60
Study: 23675788

Group type: EXPERIMENTAL
Intervention: 3-month jump-landing training program
Number of subjects: 243
Study: 21627686

Group type: EXPERIMENTAL
Intervention: Higher-dose angiotensin receptor blockers
Number of subjects: 1051

Group type: COMPARATOR
Intervention: Lower-dose angiotensin receptor blockers
Number of subjects: 1051
Study: 19320697

Group type: EXPERIMENTAL
Intervention: Personalised Advice‐giving; combination of 'Information Management' activities and 'Interactive Orientation'
Number of subjects: 106
Study: 16764345

Group type: EXPERIMENTAL
Intervention: Oral levocarnitine, 3-6 g daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immunosuppressive or immunomodulatory therapies
Number of subjects: 0
Study: 15168381

Group type: EXPERIMENTAL
Intervention: URR greater-than-75%
Number of subjects: 74120

Group type: COMPARATOR
Intervention: URR 70%-to-75%
Number of subjects: 74120

Group type: EXPERIMENTAL
Intervention: URR > or = 65%
Number of subjects: 74120
Study: 11327064

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (160 mJ/pulse, 10 Hz)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 20
Study: 9470829

Group type: EXPERIMENTAL
Intervention: rIFN-gamma 4 million units (0.2 mg) subcutaneously every other day for 4 months
Number of subjects: 120

Group type: COMPARATOR
Intervention: Observation (no maintenance therapy)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: rIFN-gamma
Number of subjects: 120
Study: 7895954

Group type: EXPERIMENTAL
Intervention: Hypoglycaemia (blood glucose 2.5 mmol/l) with 90 degrees headup posture
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hypoglycaemia (blood glucose 2.5 mmol/l) with return to supine posture
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hypoglycaemia (blood glucose 2.5 mmol/l) after 40 min
Number of subjects: 10

Group type: COMPARATOR
Intervention: Euglycaemia (blood glucose 5.0 mmol/l) using a hyperinsulinaemic clamp
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Standing maintained during hypoglycaemia
Number of subjects: 10
Study: 2879101

Group type: EXPERIMENTAL
Intervention: 1 microgram dose of Merck, Sharp and Dohme plasma vaccine
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: 2 micrograms dose of Merck, Sharp and Dohme plasma vaccine
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Three 2 micrograms doses of vaccine
Number of subjects: 119
Study: 31318424

Group type: EXPERIMENTAL
Intervention: Serologic testing for anti-measles virus IgG antibody in a subsample of survey participants.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard estimate based on positive recall or HBR documentation.
Number of subjects: 0
Study: 27241450

Group type: EXPERIMENTAL
Intervention: Active rTMS (1250 pulses at 10 Hz for 10 sessions over 2 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham rTMS (n=6)
Number of subjects: 12
Study: 25774645

Group type: EXPERIMENTAL
Intervention: PCI with everolimus-eluting stents
Number of subjects: 880

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 880
Study: 24128322

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) plus adjuvant systemic therapy
Number of subjects: 86

Group type: COMPARATOR
Intervention: Adjuvant systemic therapy alone (Control)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Persistent DTC 12 months after diagnosis
Number of subjects: 86
Study: 21271803

Group type: EXPERIMENTAL
Intervention: Conventional adaptive directional hearing aid
Number of subjects: 21

Group type: COMPARATOR
Intervention: Omnidirectional hearing aid
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Adaptive directional with anti-cardioid algorithm
Number of subjects: 21
Study: 19269753

Group type: EXPERIMENTAL
Intervention: VAC BNO 1095 extract (40mg herbal drug)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study: 16763787

Group type: EXPERIMENTAL
Intervention: Anvirzel (0.1, 0.2, 0.4, 0.8, 1.2 ml/m2/day)
Number of subjects: 18
Study: 12783047

Group type: EXPERIMENTAL
Intervention: C+E (Caffeine 4 mg x kg‐1 + Ephedrine 0.8 mg x kg‐1)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: E (Ephedrine 0.8 mg x kg‐1)
Number of subjects: 13

Group type: COMPARATOR
Intervention: C (Caffeine 4 mg x kg‐1)
Number of subjects: 13

Group type: COMPARATOR
Intervention: P (Placebo)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: C+E and E (combined)
Number of subjects: 13

Group type: COMPARATOR
Intervention: C (Caffeine) and P (Placebo)
Number of subjects: 13
Study: 11049012

Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water
Number of subjects: 10
Study: 9323668

Group type: EXPERIMENTAL
Intervention: Dodecafluoropentane
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 20
Study: 8378743

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 9
Study: 3758239

Group type: EXPERIMENTAL
Intervention: Nebuhaler (terbutaline 0.10 mg/kg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nebulizer (terbutaline 0.10 mg/kg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Nebuhaler
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nebulizer
Number of subjects: 21
Study: 28757316

Group type: EXPERIMENTAL
Intervention: WATS in conjunction with biopsy sampling
Number of subjects: 160

Group type: COMPARATOR
Intervention: Biopsy sampling alone
Number of subjects: 160
Study: 27031862

Group type: EXPERIMENTAL
Intervention: Verum acupressure
Number of subjects: 150

Group type: COMPARATOR
Intervention: Sham acupressure
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study: 24089509

Group type: EXPERIMENTAL
Intervention: Intensive treatment group with a 50% higher stimulated C-peptide on entry (from 0.10 to 0.15 nmol/L)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive treatment group with a 50% higher stimulated C-peptide on entry
Number of subjects: 0
Study: 22789125

Group type: EXPERIMENTAL
Intervention: Eltrombopag (12.5mg to 50mg daily)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (unexposed to TPR‐A)
Number of subjects: 37
Study: 20429948

Group type: EXPERIMENTAL
Intervention: Nurse-led telephone follow-up
Number of subjects: 299

Group type: COMPARATOR
Intervention: Traditional hospital follow-up
Number of subjects: 299
Study: 18515595

Group type: EXPERIMENTAL
Intervention: Caucasian group
Number of subjects: 83

Group type: COMPARATOR
Intervention: African American group
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Male group
Number of subjects: 83

Group type: COMPARATOR
Intervention: Female group
Number of subjects: 83
Study: 16518002

Group type: COMPARATOR
Intervention: Once daily dosing (ODD) - 160 mg once daily
Number of subjects: 52

Group type: COMPARATOR
Intervention: Pharmacokinetic dosing (TCI) - 160 mg once daily initially, dose revised based on serum drug levels
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Control group (CG) - 80 mg gentamicin twice daily
Number of subjects: 52
Study: 12818938

Group type: EXPERIMENTAL
Intervention: Chin Lift (CL)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Jaw Thrust (JT)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) at 5 cm H(2)O with JT
Number of subjects: 16

Group type: COMPARATOR
Intervention: Baseline (no intervention)
Number of subjects: 16
Study: 12439841

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg orally twice daily on the day before and the day of contrast administration with hydration
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group with hydration protocol using hypotonic saline
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) in patients with mild renal failure
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group in patients with mild renal failure
Number of subjects: 100

Group type: COMPARATOR
Intervention: N-acetylcysteine (NAC) and control group
Number of subjects: 100
Study: 9719082

Group type: EXPERIMENTAL
Intervention: DFMO 0.20 g/m2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DFMO 0.40 g/m2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DFMO (all doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DFMO (0.20 g/m2 and 0.40 g/m2)
Number of subjects: 0
Study: 7868408

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam
Number of subjects: 299

Group type: COMPARATOR
Intervention: Ticarcillin/clavulanate
Number of subjects: 299
Study: 2582668

Group type: EXPERIMENTAL
Intervention: Core decompression and grafting with electrical stimulation
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Core decompression and grafting without electrical stimulation
Number of subjects: 116

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 116
Study: 4919027

Group type: EXPERIMENTAL
Intervention: Oral L-DOPA
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard agents
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Combination of drugs
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: L-DOPA
Number of subjects: 23
Study: 30601228

Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 6190

Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 6190
Study: 28161927

Group type: EXPERIMENTAL
Intervention: 0.5% levofloxacin eye drops for 1 day (6 times/d)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: 0.5% levofloxacin eye drops for 2 days (3 times/d)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: 0.5% levofloxacin eye drops for 3 days (3 times/d)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 209
Study: 25989732

Group type: EXPERIMENTAL
Intervention: FAHT cream
Number of subjects: 233

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study: 23884317

Group type: EXPERIMENTAL
Intervention: Distress Tolerance (DT) treatment (9 2-hr group and 6 50-min individual sessions) plus 8 weeks of transdermal nicotine patch
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard Smoking Treatment (ST) (6 90-min group and 1 20-min individual session) plus 8 weeks of transdermal nicotine patch
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Distress Tolerance (DT) treatment
Number of subjects: 49
Study: 21854342

Group type: COMPARATOR
Intervention: Mometasone furoate delivered via dry powder inhaler (MF-DPI) 100 μg once daily in the morning (QD AM)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Mometasone furoate delivered via dry powder inhaler (MF-DPI) 100 μg twice daily (BID)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Mometasone furoate delivered via dry powder inhaler (MF-DPI) 200 μg once daily in the morning (QD AM)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study: 19394468

Group type: EXPERIMENTAL
Intervention: Regular soda consumption
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Fast-food restaurant use
Number of subjects: 145

Group type: COMPARATOR
Intervention: Sugar-sweetened beverages consumption
Number of subjects: 145

Group type: COMPARATOR
Intervention: High-fat foods consumption
Number of subjects: 145

Group type: COMPARATOR
Intervention: Fast-food restaurant use frequency
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Fruit/vegetable intake
Number of subjects: 145

Group type: COMPARATOR
Intervention: Regular soda consumption and socioeconomic status
Number of subjects: 145
Study: 16567155

Group type: EXPERIMENTAL
Intervention: High protein (3.6 g/kg/day)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Moderate protein (1.8 g/kg/day)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Low protein (0.8 g/kg/day)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Fluid intake and fluid balance
Number of subjects: 5
Study: 12507714

Group type: EXPERIMENTAL
Intervention: Immediate-release morphine given 4-hourly
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sustained-release morphine given once daily
Number of subjects: 40
Study: 10844490

Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg i.m.
Number of subjects: 25

Group type: COMPARATOR
Intervention: Diphenhydramine 50 mg i.m.
Number of subjects: 25
Study: 9117221

Group type: EXPERIMENTAL
Intervention: 1.0% glycine
Number of subjects: 77

Group type: COMPARATOR
Intervention: 1.5% glycine
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 1% ethanol
Number of subjects: 77
Study: 8229755

Group type: EXPERIMENTAL
Intervention: Cocaine (0, 12.5, 25 and 50 mg, i.v.)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Mazindol (0, 1 and 2 mg given orally 2 hr before the cocaine injection)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cocaine + Mazindol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Cocaine alone
Number of subjects: 8
Study: 30246320

Group type: EXPERIMENTAL
Intervention: Inhaled procaterol
Number of subjects: 37

Group type: COMPARATOR
Intervention: Normal saline solution (placebo)
Number of subjects: 37
Study: 27232900

Group type: EXPERIMENTAL
Intervention: Wearing Etafilcon A contact lenses
Number of subjects: 30

Group type: COMPARATOR
Intervention: No lens wear
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both stages (lens wear and no lens wear)
Number of subjects: 30
Study: 24141472

Group type: EXPERIMENTAL
Intervention: Multilevel pressure measurements during polysomnography (PSG) on one night
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard polysomnography (PSG) without pressure measurements on the other night
Number of subjects: 51
Study: 22322921

Group type: EXPERIMENTAL
Intervention: Intensive reinforced DE-PLAN intervention (n = 333)
Number of subjects: 2054

Group type: COMPARATOR
Intervention: Standard care (n = 219)
Number of subjects: 2054

Group type: EXPERIMENTAL
Intervention: Intensive intervention
Number of subjects: 2054
Study: 20189465

Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (SG)
Number of subjects: 67
Study: 18719756

Group type: EXPERIMENTAL
Intervention: Pelvic floor exercises
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Vaginal cones
Number of subjects: 118

Group type: COMPARATOR
Intervention: No active treatment (control)
Number of subjects: 118
Study: 15821318

Group type: EXPERIMENTAL
Intervention: Cerasorbe
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 127
Study: 12427202

Group type: EXPERIMENTAL
Intervention: Button-bracket splint (BS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Resin splint (RS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Wire-composite splint (WCS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Titanium trauma splint (TTS)
Number of subjects: 10
Study: 10493325

Group type: EXPERIMENTAL
Intervention: Clinical pharmacist evaluation including medication evaluation, therapeutic recommendations, patient education, and follow-up telemonitoring
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Clinical pharmacist evaluation
Number of subjects: 181

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 181
Study: 7495583

Group type: EXPERIMENTAL
Intervention: Continuous warm blood cardioplegia (Group 2 - 58 patients)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Intermittent cold blood cardioplegia (Group 1 - 50 patients)
Number of subjects: 108
Study: 1722704

Group type: EXPERIMENTAL
Intervention: Scatter photocoagulation treatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 18
Study: 7066635

Group type: EXPERIMENTAL
Intervention: ioxaglate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: diatrizoate
Number of subjects: 20
Study: 30858146

Group type: EXPERIMENTAL
Intervention: Underweight patients (BMI < 18.5 kg/m2)
Number of subjects: 38579
Study: 28560519

Group type: EXPERIMENTAL
Intervention: Hydrogen-generating minerals (6 ppm of H2 per day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 26704611

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 3381

Group type: COMPARATOR
Intervention: Suppressive acyclovir therapy
Number of subjects: 3381
Study: 24465617

Group type: EXPERIMENTAL
Intervention: High-dose micronutrient and anti-oxidant supplementation
Number of subjects: 127

Group type: COMPARATOR
Intervention: Recommended daily allowance (RDA) vitamins
Number of subjects: 127
Study: 22647387

Group type: EXPERIMENTAL
Intervention: Continuous, all-layer suture technique using slowly absorbable monofilament material (two Monoplus loops)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Interrupted suture technique using rapidly absorbable braided material (Vicryl sutures)
Number of subjects: 80
Study: 20637561

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Compressed air (HBA)
Number of subjects: 20
Study: 18408402

Group type: EXPERIMENTAL
Intervention: Screening for breast cancer (clinical breast examination)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening for cervix cancer (visual inspection of the cervix after application of 4% acetic acid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment for breast cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment for cervix cancers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment for cervix pre-cancers
Number of subjects: 0
Study: 15083365

Group type: EXPERIMENTAL
Intervention: Controlled aerobic training for 8 weeks (6 sessions/week, 45 min each at 70-80% max heart rate) followed by a 10-month home-based training program
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Controlled aerobic training for 8 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Home-based training program for 10 months
Number of subjects: 24
Study: 11786110

Group type: COMPARATOR
Intervention: LdCa (1.25 mmol/L)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: dCaP (1.25 mmol/L for first 2 hours, 1.75 mmol/L for last 2 hours)
Number of subjects: 18

Group type: COMPARATOR
Intervention: MdCa (1.5 mmol/L)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: dCaP
Number of subjects: 18
Study: 9838746

Group type: EXPERIMENTAL
Intervention: Funoran containing chewing gum (FG)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Eucalyptus extract containing chewing gum (EG)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control gum
Number of subjects: 15
Study: 7861833

Group type: EXPERIMENTAL
Intervention: Prophylactic amphotericin B (AmB) at a dose of 0.5 mg/kg/48 h from day + 1 BMT until hemoperipheral recovery (group A)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (group B) who did not receive prophylactic AmB
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Prophylactic amphotericin B (AmB) (group A)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 45
Study: 2683457

Group type: EXPERIMENTAL
Intervention: Oral vaccine (0.55 microgram active components, administered intermittently over six months)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Oral vaccine (6 or 9 capsules per day)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Oral vaccine
Number of subjects: 22
Study: 4448869

Group type: EXPERIMENTAL
Intervention: Noncontingently warm and rewarding model
Number of subjects: 36

Group type: COMPARATOR
Intervention: Neutral and nonrewarding model
Number of subjects: 36

Group type: COMPARATOR
Intervention: No model exposure
Number of subjects: 36
Study: 31533750

Group type: EXPERIMENTAL
Intervention: Modified SB (600 mg·kg‐1 over 19.5 h)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Acute SB (300 mg·kg‐1)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Modified SB
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Acute SB
Number of subjects: 7
Study: 27889845

Group type: EXPERIMENTAL
Intervention: PROGRIP (self-gripping semi re-absorbable mesh)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Polypropylene (traditional polypropylene mesh)
Number of subjects: 45
Study: 26307568

Group type: EXPERIMENTAL
Intervention: Neurogenetic evidence presented by prosecution
Number of subjects: 372

Group type: COMPARATOR
Intervention: Psychiatric diagnosis of psychopathy presented by prosecution
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Neurogenetic evidence presented by defence
Number of subjects: 372

Group type: COMPARATOR
Intervention: Psychiatric diagnosis of psychopathy presented by defence
Number of subjects: 372
Study: 24310987

Group type: EXPERIMENTAL
Intervention: Vaginal packing (n=86)
Number of subjects: 190

Group type: COMPARATOR
Intervention: No vaginal packing (n=87)
Number of subjects: 190
Study: 22480515

Group type: EXPERIMENTAL
Intervention: SLV-306 (daglutril)
Number of subjects: 13
Study: 19353750

Group type: EXPERIMENTAL
Intervention: Irradiated allograft
Number of subjects: 68

Group type: COMPARATOR
Intervention: Autograft
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 68